Zevra Therapeutics, Inc. (FRA:1GDA)

Market Cap	409.28M
Revenue (ttm)	71.92M
Net Income (ttm)	25.58M
Shares Out	n/a
EPS (ttm)	0.46
PE Ratio	16.00
Forward PE	17.19
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	107
Open	7.55
Previous Close	7.30
Day's Range	7.55 - 7.55
52-Week Range	5.75 - 10.80
Beta	n/a
RSI	43.09
Earnings Date	Mar 6, 2026

About Zevra Therapeutics

Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase 1/2 clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 3 clinical tria...

• Industry: Pharmaceutical Preparations
• Founded: 2006
• Employees: 59
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 1GDA

Financial Performance

In 2024, Zevra Therapeutics's revenue was $23.61 million, a decrease of -14.02% compared to the previous year's $27.46 million. Losses were -$105.51 million, 129.1% more than in 2023.

Financial numbers in USD